ID   CP2C8_HUMAN             Reviewed;         490 AA.
AC   P10632; A8K9N8; B0AZN2; B7Z1F6; Q5VX93; Q8WWB1; Q9UCZ9;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 2.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Cytochrome P450 2C8;
DE            EC=1.14.14.1 {ECO:0000269|PubMed:7574697};
DE   AltName: Full=CYPIIC8;
DE   AltName: Full=Cytochrome P450 IIC2;
DE   AltName: Full=Cytochrome P450 MP-12;
DE   AltName: Full=Cytochrome P450 MP-20;
DE   AltName: Full=Cytochrome P450 form 1;
DE   AltName: Full=S-mephenytoin 4-hydroxylase;
GN   Name=CYP2C8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-264.
RC   TISSUE=Liver;
RX   PubMed=3500169;
RA   Okino S.T., Quattrochi L.C., Pendurthi U.R., McBride O.W., Tukey R.H.;
RT   "Characterization of multiple human cytochrome P-450 1 cDNAs. The
RT   chromosomal localization of the gene and evidence for alternate RNA
RT   splicing.";
RL   J. Biol. Chem. 262:16072-16079(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=3697070; DOI=10.1093/nar/15.23.10053;
RA   Kimura S., Pastewka J., Gelboin H.V., Gonzalez F.J.;
RT   "cDNA and amino acid sequences of two members of the human P450IIC
RT   gene subfamily.";
RL   Nucleic Acids Res. 15:10053-10054(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-264.
RX   PubMed=2009263; DOI=10.1021/bi00227a012;
RA   Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A.;
RT   "Cloning and expression of complementary DNAs for multiple members of
RT   the human cytochrome P450IIC subfamily.";
RL   Biochemistry 30:3247-3255(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS LYS-139 AND ARG-399.
RC   TISSUE=Liver, and Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-139; VAL-244;
RP   MET-264; PHE-269 AND ARG-399.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-56.
RC   TISSUE=Blood;
RX   PubMed=1707679; DOI=10.1016/0167-4781(91)90138-C;
RA   Ged C., Beaune P.;
RT   "Isolation of the human cytochrome P-450 IIC8 gene: multiple
RT   glucocorticoid responsive elements in the 5' region.";
RL   Biochim. Biophys. Acta 1088:433-435(1991).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-15, NUCLEOTIDE SEQUENCE [MRNA] OF 6-490,
RP   FUNCTION, CATALYTIC ACTIVITY, AND VARIANT LEU-411.
RC   TISSUE=Kidney;
RX   PubMed=7574697; DOI=10.1006/abbi.1995.1438;
RA   Zeldin D.C., DuBois R.N., Falck J.R., Capdevila J.H.;
RT   "Molecular cloning, expression and characterization of an endogenous
RT   human cytochrome P450 arachidonic acid epoxygenase isoform.";
RL   Arch. Biochem. Biophys. 322:76-86(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 11-490 (ISOFORM 1), AND VARIANTS
RP   ASP-154; LYS-193; ARG-249 AND LEU-411.
RC   TISSUE=Liver;
RX   PubMed=3196692; DOI=10.1021/bi00418a039;
RA   Ged C., Umbenhauer D.R., Bellew T.M., Bork R.W., Srivastava P.K.,
RA   Shinriki N., Lloyd R.S., Guengerich F.P.;
RT   "Characterization of cDNAs, mRNAs, and proteins related to human liver
RT   microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase.";
RL   Biochemistry 27:6929-6940(1988).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 34-382 (ISOFORM 1), AND VARIANT LYS-139.
RX   PubMed=2729895; DOI=10.1111/j.1469-1809.1989.tb01119.x;
RA   Shephard E.A., Phillips I.R., Santisteban I., Palmer C.N., Povey S.;
RT   "Cloning, expression and chromosomal localization of a member of the
RT   human cytochrome P450IIC gene sub-family.";
RL   Ann. Hum. Genet. 53:23-31(1989).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 281-490 (ISOFORM 1), AND VARIANT
RP   ARG-399.
RX   PubMed=2216732; DOI=10.1093/nar/18.18.5550;
RA   Kolyada A.Y.;
RT   "Sequence of a human liver cytochrome P-450 cDNA clone.";
RL   Nucleic Acids Res. 18:5550-5550(1990).
RN   [14]
RP   POLYMORPHISM.
RX   PubMed=15365880; DOI=10.1007/s10038-004-0188-6;
RA   Ishikawa C., Ozaki H., Nakajima T., Ishii T., Kanai S., Anjo S.,
RA   Shirai K., Inoue I.;
RT   "A frameshift variant of CYP2C8 was identified in a patient who
RT   suffered from rhabdomyolysis after administration of cerivastatin.";
RL   J. Hum. Genet. 49:582-585(2004).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 28-490.
RX   PubMed=14676196; DOI=10.1074/jbc.M312516200;
RA   Schoch G.A., Yano J.K., Wester M.R., Griffin K.J., Stout C.D.,
RA   Johnson E.F.;
RT   "Structure of human microsomal cytochrome P450 2C8. Evidence for a
RT   peripheral fatty acid binding site.";
RL   J. Biol. Chem. 279:9497-9503(2004).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 28-490 IN COMPLEX WITH
RP   INHIBITORS, AND SUBSTRATE-BINDING SITES.
RX   PubMed=18413310; DOI=10.1074/jbc.M802180200;
RA   Schoch G.A., Yano J.K., Sansen S., Dansette P.M., Stout C.D.,
RA   Johnson E.F.;
RT   "Determinants of cytochrome P450 2C8 substrate binding: structures of
RT   complexes with montelukast, troglitazone, felodipine, and 9-cis-
RT   retinoic acid.";
RL   J. Biol. Chem. 283:17227-17237(2008).
RN   [18]
RP   VARIANTS LYS-139; PHE-269 AND ARG-399.
RX   PubMed=11668219; DOI=10.1097/00008571-200110000-00006;
RA   Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J.,
RA   Ghanayem B.I., Goldstein J.A.;
RT   "Polymorphisms in human CYP2C8 decrease metabolism of the anticancer
RT   drug paclitaxel and arachidonic acid.";
RL   Pharmacogenetics 11:597-607(2001).
RN   [19]
RP   VARIANTS LYS-139; MET-264; PHE-269; SER-390 AND ARG-399.
RX   PubMed=12429347; DOI=10.1016/S0006-2952(02)01354-0;
RA   Bahadur N., Leathart J.B., Mutch E., Steimel-Crespi D., Dunn S.A.,
RA   Gilissen R., Houdt J.V., Hendrickx J., Mannens G., Bohets H.,
RA   Williams F.M., Armstrong M., Crespi C.L., Daly A.K.;
RT   "CYP2C8 polymorphisms in Caucasians and their relationship with
RT   paclitaxel 6alpha-hydroxylase activity in human liver microsomes.";
RL   Biochem. Pharmacol. 64:1579-1589(2002).
RN   [20]
RP   VARIANTS LYS-139; MET-264; PHE-269 AND ARG-399.
RX   PubMed=15469410; DOI=10.1517/14622416.5.7.895;
RA   Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q.,
RA   McMunn C., Ihrie P., Mehall J.M., Edwards T.L., Dawson E.P.;
RT   "Genetic variation in eleven phase I drug metabolism genes in an
RT   ethnically diverse population.";
RL   Pharmacogenomics 5:895-931(2004).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS LYS-139; SER-171; GLY-186; MET-223;
RP   PRO-238; ARG-247; MET-264; PHE-269; ASN-383; ARG-399 AND VAL-461 DEL,
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=26427316; DOI=10.1016/j.dmpk.2015.07.003;
RA   Tsukada C., Saito T., Maekawa M., Mano N., Oda A., Hirasawa N.,
RA   Hiratsuka M.;
RT   "Functional characterization of 12 allelic variants of CYP2C8 by
RT   assessment of paclitaxel 6alpha-hydroxylation and amodiaquine N-
RT   deethylation.";
RL   Drug Metab. Pharmacokinet. 30:366-373(2015).
CC   -!- FUNCTION: Cytochromes P450 are a group of heme-thiolate
CC       monooxygenases. In liver microsomes, this enzyme is involved in an
CC       NADPH-dependent electron transport pathway. It oxidizes a variety
CC       of structurally unrelated compounds, including steroids, fatty
CC       acids, and xenobiotics. In the epoxidation of arachidonic acid it
CC       generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It
CC       is the principal enzyme responsible for the metabolism the anti-
CC       cancer drug paclitaxel (taxol). {ECO:0000269|PubMed:26427316,
CC       ECO:0000269|PubMed:7574697}.
CC   -!- CATALYTIC ACTIVITY: RH + [reduced NADPH--hemoprotein reductase] +
CC       O(2) = ROH + [oxidized NADPH--hemoprotein reductase] + H(2)O.
CC       {ECO:0000269|PubMed:7574697}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.18 uM for paclitaxel {ECO:0000269|PubMed:26427316};
CC         KM=1.35 uM for amodiaquine {ECO:0000269|PubMed:26427316};
CC         Vmax=2.18 pmol/min/pmol enzyme with paclitaxel as substrate
CC         {ECO:0000269|PubMed:26427316};
CC         Vmax=11.30 pmol/min/pmol enzyme with amodiaquine as substrate
CC         {ECO:0000269|PubMed:26427316};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P10632-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P10632-2; Sequence=VSP_043306, VSP_043307;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: By phenobarbital.
CC   -!- POLYMORPHISM: Several alleles are found in the human population,
CC       contributing to interindividual variations in the therapeutic
CC       efficacy and toxicity of a myriad of drugs such as paclitaxel or
CC       amodiaquine. The allele shown here is CYP2C8*1 (PubMed:26427316).
CC       CYP2C8 genetic variations may be associated with adverse effects
CC       of cerivastatin including acute rhabdomyolysis [MIM:601129].
CC       {ECO:0000269|PubMed:26427316}.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- CAUTION: Alternative splicing has been shown to occur but the
CC       shorter forms are believed to be non-functional. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Cytochrome P450 Allele Nomenclature Committee;
CC       Note=CYP2C8 alleles;
CC       URL="http://www.cypalleles.ki.se/cyp2c8.htm";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cyp2c8/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M17397; AAA35739.1; -; mRNA.
DR   EMBL; M17398; AAA35740.1; -; mRNA.
DR   EMBL; Y00498; CAA68550.1; -; mRNA.
DR   EMBL; AK292753; BAF85442.1; -; mRNA.
DR   EMBL; AK293328; BAH11492.1; -; mRNA.
DR   EMBL; AK315823; BAF98714.1; -; mRNA.
DR   EMBL; AY514490; AAR89907.1; -; Genomic_DNA.
DR   EMBL; AL359672; CAH71307.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50018.1; -; Genomic_DNA.
DR   EMBL; BC020596; AAH20596.1; -; mRNA.
DR   EMBL; X54807; CAA38578.1; -; Genomic_DNA.
DR   EMBL; M21941; AAA52160.1; -; mRNA.
DR   EMBL; M21942; AAA52161.1; -; mRNA.
DR   EMBL; X51535; CAA35915.1; -; mRNA.
DR   CCDS; CCDS55721.1; -. [P10632-2]
DR   CCDS; CCDS7438.1; -. [P10632-1]
DR   PIR; A29782; A29782.
DR   RefSeq; NP_000761.3; NM_000770.3. [P10632-1]
DR   RefSeq; NP_001185782.1; NM_001198853.1.
DR   RefSeq; NP_001185783.1; NM_001198854.1. [P10632-2]
DR   RefSeq; NP_001185784.1; NM_001198855.1.
DR   UniGene; Hs.709188; -.
DR   PDB; 1PQ2; X-ray; 2.70 A; A/B=19-490.
DR   PDB; 2NNH; X-ray; 2.60 A; A/B=28-490.
DR   PDB; 2NNI; X-ray; 2.80 A; A=28-490.
DR   PDB; 2NNJ; X-ray; 2.28 A; A=28-490.
DR   PDB; 2VN0; X-ray; 2.70 A; A=28-490.
DR   PDBsum; 1PQ2; -.
DR   PDBsum; 2NNH; -.
DR   PDBsum; 2NNI; -.
DR   PDBsum; 2NNJ; -.
DR   PDBsum; 2VN0; -.
DR   ProteinModelPortal; P10632; -.
DR   SMR; P10632; -.
DR   BioGrid; 107936; 14.
DR   IntAct; P10632; 10.
DR   STRING; 9606.ENSP00000360317; -.
DR   BindingDB; P10632; -.
DR   ChEMBL; CHEMBL3721; -.
DR   DrugBank; DB05812; Abiraterone.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00918; Almotriptan.
DR   DrugBank; DB01424; Aminophenazone.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00613; Amodiaquine.
DR   DrugBank; DB00701; Amprenavir.
DR   DrugBank; DB01435; Antipyrine.
DR   DrugBank; DB06605; Apixaban.
DR   DrugBank; DB01076; Atorvastatin.
DR   DrugBank; DB00972; Azelastine.
DR   DrugBank; DB06770; Benzyl alcohol.
DR   DrugBank; DB05229; Beraprost.
DR   DrugBank; DB01393; Bezafibrate.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB01156; Bupropion.
DR   DrugBank; DB06772; Cabazitaxel.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00796; Candesartan.
DR   DrugBank; DB00564; Carbamazepine.
DR   DrugBank; DB00748; Carbinoxamine.
DR   DrugBank; DB00439; Cerivastatin.
DR   DrugBank; DB00446; Chloramphenicol.
DR   DrugBank; DB00608; Chloroquine.
DR   DrugBank; DB00169; Cholecalciferol.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB00758; Clopidogrel.
DR   DrugBank; DB00257; Clotrimazole.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB01394; Colchicine.
DR   DrugBank; DB00531; Cyclophosphamide.
DR   DrugBank; DB00091; Cyclosporine.
DR   DrugBank; DB08912; Dabrafenib.
DR   DrugBank; DB00250; Dapsone.
DR   DrugBank; DB09183; Dasabuvir.
DR   DrugBank; DB00705; Delavirdine.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB00647; Dextropropoxyphene.
DR   DrugBank; DB00829; Diazepam.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB00343; Diltiazem.
DR   DrugBank; DB01184; Domperidone.
DR   DrugBank; DB06210; Eltrombopag.
DR   DrugBank; DB08899; Enzalutamide.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00402; Eszopiclone.
DR   DrugBank; DB00977; Ethinyl Estradiol.
DR   DrugBank; DB00773; Etoposide.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB01039; Fenofibrate.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB01095; Fluvastatin.
DR   DrugBank; DB01320; Fosphenytoin.
DR   DrugBank; DB01241; Gemfibrozil.
DR   DrugBank; DB01218; Halofantrine.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB09054; Idelalisib.
DR   DrugBank; DB01181; Ifosfamide.
DR   DrugBank; DB01029; Irbesartan.
DR   DrugBank; DB00951; Isoniazid.
DR   DrugBank; DB09570; Ixazomib.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB01009; Ketoprofen.
DR   DrugBank; DB00448; Lansoprazole.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB08918; Levomilnacipran.
DR   DrugBank; DB00451; Levothyroxine.
DR   DrugBank; DB04725; Licofelone.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB01583; Liotrix.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB00455; Loratadine.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB00227; Lovastatin.
DR   DrugBank; DB09280; Lumacaftor.
DR   DrugBank; DB00603; Medroxyprogesterone acetate.
DR   DrugBank; DB00784; Mefenamic acid.
DR   DrugBank; DB00814; Meloxicam.
DR   DrugBank; DB00532; Mephenytoin.
DR   DrugBank; DB00333; Methadone.
DR   DrugBank; DB00916; Metronidazole.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00764; Mometasone.
DR   DrugBank; DB00471; Montelukast.
DR   DrugBank; DB00295; Morphine.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB00788; Naproxen.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB00665; Nilutamide.
DR   DrugBank; DB06712; Nilvadipine.
DR   DrugBank; DB09080; Olodaterol.
DR   DrugBank; DB09296; Ombitasvir.
DR   DrugBank; DB00338; Omeprazole.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB01229; Paclitaxel.
DR   DrugBank; DB03796; Palmitic Acid.
DR   DrugBank; DB00617; Paramethadione.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB00738; Pentamidine.
DR   DrugBank; DB00850; Perphenazine.
DR   DrugBank; DB00780; Phenelzine.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB00946; Phenprocoumon.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB01132; Pioglitazone.
DR   DrugBank; DB00554; Piroxicam.
DR   DrugBank; DB08860; Pitavastatin.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB00175; Pravastatin.
DR   DrugBank; DB00794; Primidone.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB01182; Propafenone.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB00205; Pyrimethamine.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00468; Quinine.
DR   DrugBank; DB00481; Raloxifene.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00912; Repaglinide.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB01201; Rifapentine.
DR   DrugBank; DB08931; Riociguat.
DR   DrugBank; DB00503; Ritonavir.
DR   DrugBank; DB00533; Rofecoxib.
DR   DrugBank; DB00412; Rosiglitazone.
DR   DrugBank; DB01698; Rutin.
DR   DrugBank; DB00938; Salmeterol.
DR   DrugBank; DB01232; Saquinavir.
DR   DrugBank; DB00418; Secobarbital.
DR   DrugBank; DB01037; Selegiline.
DR   DrugBank; DB11362; Selexipag.
DR   DrugBank; DB00641; Simvastatin.
DR   DrugBank; DB01261; Sitagliptin.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00359; Sulfadiazine.
DR   DrugBank; DB01015; Sulfamethoxazole.
DR   DrugBank; DB06729; Sulfaphenazole.
DR   DrugBank; DB01138; Sulfinpyrazone.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00799; Tazarotene.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB00231; Temazepam.
DR   DrugBank; DB00857; Terbinafine.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB00277; Theophylline.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB00208; Ticlopidine.
DR   DrugBank; DB01007; Tioconazole.
DR   DrugBank; DB01124; Tolbutamide.
DR   DrugBank; DB00214; Torasemide.
DR   DrugBank; DB08911; Trametinib.
DR   DrugBank; DB00755; Tretinoin.
DR   DrugBank; DB00897; Triazolam.
DR   DrugBank; DB00347; Trimethadione.
DR   DrugBank; DB00440; Trimethoprim.
DR   DrugBank; DB00197; Troglitazone.
DR   DrugBank; DB01361; Troleandomycin.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB08828; Vismodegib.
DR   DrugBank; DB09068; Vortioxetine.
DR   DrugBank; DB00682; Warfarin.
DR   DrugBank; DB00549; Zafirlukast.
DR   DrugBank; DB00495; Zidovudine.
DR   DrugBank; DB01198; Zopiclone.
DR   GuidetoPHARMACOLOGY; 1325; -.
DR   SwissLipids; SLP:000001548; -.
DR   SwissLipids; SLP:000001616; -. [P10632-1]
DR   iPTMnet; P10632; -.
DR   PhosphoSitePlus; P10632; -.
DR   BioMuta; CYP2C8; -.
DR   DMDM; 117225; -.
DR   PaxDb; P10632; -.
DR   PeptideAtlas; P10632; -.
DR   PRIDE; P10632; -.
DR   DNASU; 1558; -.
DR   Ensembl; ENST00000371270; ENSP00000360317; ENSG00000138115. [P10632-1]
DR   Ensembl; ENST00000535898; ENSP00000445062; ENSG00000138115. [P10632-2]
DR   GeneID; 1558; -.
DR   KEGG; hsa:1558; -.
DR   UCSC; uc001kkb.4; human. [P10632-1]
DR   CTD; 1558; -.
DR   DisGeNET; 1558; -.
DR   GeneCards; CYP2C8; -.
DR   HGNC; HGNC:2622; CYP2C8.
DR   HPA; HPA013547; -.
DR   HPA; HPA013970; -.
DR   HPA; HPA015066; -.
DR   MalaCards; CYP2C8; -.
DR   MIM; 601129; gene+phenotype.
DR   neXtProt; NX_P10632; -.
DR   OpenTargets; ENSG00000138115; -.
DR   PharmGKB; PA125; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118775; -.
DR   HOGENOM; HOG000036992; -.
DR   HOVERGEN; HBG015789; -.
DR   InParanoid; P10632; -.
DR   KO; K17718; -.
DR   OMA; MLQIDIK; -.
DR   OrthoDB; EOG091G0BT8; -.
DR   PhylomeDB; P10632; -.
DR   TreeFam; TF352043; -.
DR   BRENDA; 1.14.14.1; 2681.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-211999; CYP2E1 reactions.
DR   Reactome; R-HSA-2142670; Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET).
DR   Reactome; R-HSA-2142816; Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE).
DR   SABIO-RK; P10632; -.
DR   EvolutionaryTrace; P10632; -.
DR   GeneWiki; CYP2C8; -.
DR   GenomeRNAi; 1558; -.
DR   PRO; PR:P10632; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000138115; -.
DR   CleanEx; HS_CYP2C8; -.
DR   ExpressionAtlas; P10632; baseline and differential.
DR   Genevisible; P10632; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008392; F:arachidonic acid epoxygenase activity; IBA:GO_Central.
DR   GO; GO:0070330; F:aromatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0034875; F:caffeine oxidase activity; IDA:BHF-UCL.
DR   GO; GO:0101020; F:estrogen 16-alpha-hydroxylase activity; IDA:BHF-UCL.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0019825; F:oxygen binding; TAS:Reactome.
DR   GO; GO:0017144; P:drug metabolic process; IDA:BHF-UCL.
DR   GO; GO:0019373; P:epoxygenase P450 pathway; IBA:GO_Central.
DR   GO; GO:0042738; P:exogenous drug catabolic process; IDA:BHF-UCL.
DR   GO; GO:0002933; P:lipid hydroxylation; IDA:BHF-UCL.
DR   GO; GO:0097267; P:omega-hydroxylase P450 pathway; TAS:Reactome.
DR   GO; GO:0006082; P:organic acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:BHF-UCL.
DR   GO; GO:0070989; P:oxidative demethylation; IDA:BHF-UCL.
DR   GO; GO:0008202; P:steroid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Endoplasmic reticulum; Heme; Iron;
KW   Membrane; Metal-binding; Microsome; Monooxygenase; Oxidoreductase;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    490       Cytochrome P450 2C8.
FT                                /FTId=PRO_0000051699.
FT   METAL       435    435       Iron (heme axial ligand).
FT   BINDING     100    100       Substrate.
FT   BINDING     204    204       Substrate.
FT   BINDING     241    241       Substrate.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     249    249       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q64458}.
FT   MOD_RES     375    375       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q64458}.
FT   VAR_SEQ       1      8       MEPFVVLV -> MFLQPIAK (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043306.
FT   VAR_SEQ       9    110       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043307.
FT   VARIANT     139    139       R -> K (in allele CYP2C8*3; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; decreases intrinsic clearance
FT                                of paclitaxel; reduces enzymatic activity
FT                                with amodiaquine as substrate;
FT                                dbSNP:rs11572080).
FT                                {ECO:0000269|PubMed:11668219,
FT                                ECO:0000269|PubMed:12429347,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:26427316,
FT                                ECO:0000269|PubMed:2729895,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_012238.
FT   VARIANT     154    154       E -> D. {ECO:0000269|PubMed:3196692}.
FT                                /FTId=VAR_001250.
FT   VARIANT     171    171       G -> S (in allele CYP2C8*6; no effect on
FT                                affinity or enzymatic activity with
FT                                paclitaxel as substrate; decreases
FT                                affinity for amodiaquine; reduces
FT                                enzymatic activity with amodiaquine as
FT                                substrate; decreases intrinsic clearance
FT                                of amodiaquine; dbSNP:rs142886225).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075541.
FT   VARIANT     186    186       R -> G (in allele CYP2C8*8; increases
FT                                affinity for paclitaxel; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; decreases intrinsic clearance
FT                                of paclitaxel; reduces enzymatic activity
FT                                with amodiaquine as substrate; decreases
FT                                intrinsic clearance of amodiaquine;
FT                                dbSNP:rs72558195).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075542.
FT   VARIANT     193    193       N -> K. {ECO:0000269|PubMed:3196692}.
FT                                /FTId=VAR_001251.
FT   VARIANT     223    223       I -> M (in allele CYP2C8*13; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; decreases intrinsic clearance
FT                                of paclitaxel; reduces enzymatic activity
FT                                with amodiaquine as substrate; decreases
FT                                intrinsic clearance of amodiaquine).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075543.
FT   VARIANT     238    238       A -> P (in allele CYP2C8*14; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; decreases intrinsic clearance
FT                                of paclitaxel; dbSNP:rs188934928).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075544.
FT   VARIANT     244    244       I -> V (in dbSNP:rs11572102).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018958.
FT   VARIANT     247    247       K -> R (in allele CYP2C8*9; increases
FT                                enzymatic activity with paclitaxel as
FT                                substrate; reduces enzymatic activity
FT                                with amodiaquine as substrate; decreases
FT                                intrinsic clearance of amodiaquine;
FT                                dbSNP:rs769460274).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075545.
FT   VARIANT     249    249       K -> R. {ECO:0000269|PubMed:3196692}.
FT                                /FTId=VAR_001252.
FT   VARIANT     264    264       I -> M (in allele CYP2C8*4; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; decreases affinity for
FT                                amodiaquine; dbSNP:rs1058930).
FT                                {ECO:0000269|PubMed:12429347,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:2009263,
FT                                ECO:0000269|PubMed:26427316,
FT                                ECO:0000269|PubMed:3500169,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011754.
FT   VARIANT     269    269       I -> F (in allele CYP2C8*2; only found in
FT                                African-Americans; increases intrinsic
FT                                clearance of paclitaxel; decreases
FT                                affinity for amodiaquine; increases
FT                                enzymatic activity with amodiaquine as
FT                                substrate; dbSNP:rs11572103).
FT                                {ECO:0000269|PubMed:11668219,
FT                                ECO:0000269|PubMed:12429347,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:26427316,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_012239.
FT   VARIANT     383    383       K -> N (in allele CYP2C8*10; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; reduces enzymatic activity
FT                                with amodiaquine as substrate; decreases
FT                                intrinsic clearance of amodiaquine).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075546.
FT   VARIANT     390    390       L -> S (in dbSNP:rs72558194).
FT                                {ECO:0000269|PubMed:12429347}.
FT                                /FTId=VAR_016947.
FT   VARIANT     399    399       K -> R (in allele CYP2C8*3; reduces
FT                                enzymatic activity with paclitaxel as
FT                                substrate; decreases intrinsic clearance
FT                                of paclitaxel; reduces enzymatic activity
FT                                with amodiaquine as substrate;
FT                                dbSNP:rs10509681).
FT                                {ECO:0000269|PubMed:11668219,
FT                                ECO:0000269|PubMed:12429347,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:2216732,
FT                                ECO:0000269|PubMed:26427316,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_012240.
FT   VARIANT     411    411       H -> L. {ECO:0000269|PubMed:3196692,
FT                                ECO:0000269|PubMed:7574697}.
FT                                /FTId=VAR_001253.
FT   VARIANT     461    461       Missing (in allele CYP2C8*12; increases
FT                                enzymatic activity with paclitaxel as
FT                                substrate; reduces enzymatic activity
FT                                with amodiaquine as substrate; decreases
FT                                intrinsic clearance of amodiaquine).
FT                                {ECO:0000269|PubMed:26427316}.
FT                                /FTId=VAR_075547.
FT   CONFLICT     54     54       F -> L (in Ref. 12; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT     67     67       V -> L (in Ref. 12; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT     76     76       V -> C (in Ref. 12; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT     82     82       A -> S (in Ref. 8; AAH20596).
FT                                {ECO:0000305}.
FT   CONFLICT    130    130       T -> N (in Ref. 1; AAA35739/AAA35740 and
FT                                3; no nucleotide entry). {ECO:0000305}.
FT   CONFLICT    209    209       N -> S (in Ref. 12; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    384    393       GTTIMALLTS -> SFDNKIMLAA (in Ref. 1;
FT                                AAA35740). {ECO:0000305}.
FT   CONFLICT    386    386       T -> A (in Ref. 4; BAF85442).
FT                                {ECO:0000305}.
FT   TURN         37     39       {ECO:0000244|PDB:2NNJ}.
FT   HELIX        42     44       {ECO:0000244|PDB:2NNJ}.
FT   STRAND       47     49       {ECO:0000244|PDB:1PQ2}.
FT   HELIX        50     61       {ECO:0000244|PDB:2NNJ}.
FT   STRAND       63     69       {ECO:0000244|PDB:2NNJ}.
FT   STRAND       72     77       {ECO:0000244|PDB:2NNJ}.
FT   HELIX        80     87       {ECO:0000244|PDB:2NNJ}.
FT   TURN         88     94       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       101    107       {ECO:0000244|PDB:2NNJ}.
FT   TURN        111    113       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       117    130       {ECO:0000244|PDB:2NNJ}.
FT   TURN        133    136       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      137    139       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       141    157       {ECO:0000244|PDB:2NNJ}.
FT   TURN        158    161       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       167    182       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      183    185       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       192    208       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       212    218       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       220    225       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       227    252       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       263    273       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       284    298       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       300    315       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       317    330       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      333    335       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       339    344       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       346    359       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      374    376       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      379    381       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      386    389       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       391    395       {ECO:0000244|PDB:2NNJ}.
FT   TURN        398    400       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      401    403       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       409    412       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       431    433       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       438    455       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      456    459       {ECO:0000244|PDB:2NNJ}.
FT   HELIX       464    466       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      472    479       {ECO:0000244|PDB:2NNJ}.
FT   STRAND      485    489       {ECO:0000244|PDB:2NNJ}.
SQ   SEQUENCE   490 AA;  55825 MW;  E920EB2084F477E1 CRC64;
     MEPFVVLVLC LSFMLLFSLW RQSCRRRKLP PGPTPLPIIG NMLQIDVKDI CKSFTNFSKV
     YGPVFTVYFG MNPIVVFHGY EAVKEALIDN GEEFSGRGNS PISQRITKGL GIISSNGKRW
     KEIRRFSLTT LRNFGMGKRS IEDRVQEEAH CLVEELRKTK ASPCDPTFIL GCAPCNVICS
     VVFQKRFDYK DQNFLTLMKR FNENFRILNS PWIQVCNNFP LLIDCFPGTH NKVLKNVALT
     RSYIREKVKE HQASLDVNNP RDFIDCFLIK MEQEKDNQKS EFNIENLVGT VADLFVAGTE
     TTSTTLRYGL LLLLKHPEVT AKVQEEIDHV IGRHRSPCMQ DRSHMPYTDA VVHEIQRYSD
     LVPTGVPHAV TTDTKFRNYL IPKGTTIMAL LTSVLHDDKE FPNPNIFDPG HFLDKNGNFK
     KSDYFMPFSA GKRICAGEGL ARMELFLFLT TILQNFNLKS VDDLKNLNTT AVTKGIVSLP
     PSYQICFIPV
//
